Caroline Wilhelmer

Caroline Wilhelmer

Auto-generated profile, based on publicly available information

Caroline Wilhelmer

Intensive Care Unit, Department of Internal Medicine, Medical University of Graz , Graz

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2025 in Clinical Infectious Diseases
Verified
Journal Article
Open access
SHStefan Hatzl
Stefan Hatzl
LKLisa Kriegl
Lisa Kriegl
CGChristina Geiger
Christina Geiger
CWCaroline Wilhelmer
Caroline Wilhelmer
ARAlexander Reisinger
Alexander Reisinger
Robert KrauseRobert Krause
Robert Krause
Background: Influenza-associated pulmonary aspergillosis (IAPA) is a significant fungal complication in patients with influenza-induced acute-respiratory-distress-syndrome (ARDS). The impact of empirical antifungal treatment on IAPA incidence and outcomes remains unclear. Methods: In this observational multicenter study (9 treatment centers), we included all consecutive patients admitted to intensive care units (ICUs) with influenza-associated ARDS between 1 September 2016 and 1 March 2025. We compared patients receiving empirical antifungal treatment with those who did not, focusing on 30-day IAPA incidence (primary outcome) and survival (secondary outcome). Propensity score weighting was used to account for baseline characteristic imbalances. IAPA cases were classified based on the Fungal-Infections-in-Adult-Patients-in-ICU (FUNDICU) consensus criteria. Results: We included 172 patients, 61 (35%) of whom received empirical antifungal therapy (94% posaconazole). IAPA was diagnosed in 24 cases, with a median onset of 2 days after ICU admission. Of these, 20 occurred in the non-treatment group and 4 in the empirical treatment group. The 30-day IAPA incidence was 7.7% in the treatment group and 20.4% in the non-treatment group (P = .002). The sub-distributional hazard ratio (sHR) for IAPA incidence in the empirical treatment group compared with the non-treatment group was 0.21 (95% CI: 0.10–0.92, P = .045). However, there was no significant difference in 30-day ICU survival. Conclusions: In ICU patients with influenza ARDS, empirical antifungal treatment was associated with significantly reduced IAPA incidence, but this did not translate into improved survival. Randomized controlled trials are warranted to evaluate the efficacy and safety of patients’ specific empirical antifungal treatment with regard to IAPA incidence and outcomes.

17 October 2026 in Clinical Infectious Diseases
Verified
Journal Article
Open access
CWCaroline Wilhelmer
Caroline Wilhelmer
LKLisa Kriegl
Lisa Kriegl
Robert KrauseRobert Krause
Robert Krause
SHStefan Hatzl
Stefan Hatzl
We reanalyzed 172 critically ill patients with influenza-associated ARDS in a Bayesian framework. Empirical mold-active antifungal treatment yielded a posterior median hazard ratio for influenza-associated pulmonary aspergillosis of 0.51 (95% credible interval 0.20-1.17; probability of benefit 94%), without mortality benefit. Findings remained consistent across skeptical, non-informative and externally informed priors.